Parkman Healthcare Partners LLC Invests $828,000 in CeriBell (NASDAQ:CBLL)

Parkman Healthcare Partners LLC bought a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 32,002 shares of the company's stock, valued at approximately $828,000. Parkman Healthcare Partners LLC owned 0.09% of CeriBell as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the company. Legal & General Group Plc purchased a new position in CeriBell during the fourth quarter worth about $32,000. Summit Investment Advisors Inc. purchased a new position in CeriBell during the fourth quarter worth about $33,000. Tower Research Capital LLC TRC purchased a new position in CeriBell during the fourth quarter worth about $37,000. BNP Paribas Financial Markets purchased a new position in CeriBell during the fourth quarter worth about $43,000. Finally, PNC Financial Services Group Inc. purchased a new position in CeriBell during the fourth quarter worth about $47,000.

Insider Activity at CeriBell

In related news, CEO Xingjuan Chao sold 15,628 shares of CeriBell stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $15.11, for a total transaction of $236,139.08. Following the transaction, the chief executive officer now owns 727,151 shares in the company, valued at approximately $10,987,251.61. The trade was a 2.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 24,700 shares of company stock worth $372,434.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CBLL. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 target price for the company. Canaccord Genuity Group reissued a "buy" rating and set a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, CeriBell currently has a consensus rating of "Buy" and a consensus target price of $32.50.

CeriBell Trading Down 3.3%

Shares of NASDAQ CBLL opened at $16.60 on Wednesday. The stock's 50 day moving average price is $17.82. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million during the quarter, compared to analyst estimates of $19.30 million. Sell-side analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.